Effect of asafoetida gum on asthma

Effect of asafoetida gum on lung function, pyroptosis factors and genes expression of IL-1b and IL-18 in asthmatic patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210909052420N1

Enrollment

Registered

2024-06-04

Start date

2024-06-20

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

Intervention 1: Control group: In this group, patients (n=46) will receive placebo capsule, twice a day, for 2 months. Intervention 2: Intervention group: In this group, patients (n=46) will receive a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of moderate-to-severe asthma based on GINA guideline Patient consent to participate in the study

Exclusion criteria

Exclusion criteria: Having systemic diseases Having inflammatory disease Having liver disease Having autoimmune diseases and immune system defects Taking drugs with antioxidant properties Taking any herbal medicine Having allergic to asafoetida Pregnancy

Design outcomes

Primary

Measure	Time frame
Respiratory symptoms. Timepoint: Before starting treatment (step 0), one (step I) and two months (step II) after starting treatment. Method of measurement: Questionnaire.;Chest wheeze. Timepoint: Before starting treatment (step 0), one (step I) and two months (step II) after starting treatment. Method of measurement: Chest auscultation.;Pulmonary function tests. Timepoint: Before starting treatment (step 0), one (step I) and two months (step II) after starting treatment. Method of measurement: Spirometer.;Cell blood count (CBC). Timepoint: Before starting treatment (step 0), one (step I) and two months (step II) after starting treatment. Method of measurement: Auto analyzer.;Oxidative stress parameters. Timepoint: Before starting treatment (step 0), and two months (step II) after starting treatment. Method of measurement: Standard kits.;Lactate dehydrogenase (LDH) in serum. Timepoint: Before starting treatment (step 0), and two months (step II) after starting treatment. Method of measurement: Standard kits.;Gene expression of IL-18 and IL-1b in sputum. Timepoint: Before starting treatment (step 0), and two months (step II) after starting treatment. Method of measurement: Standard kits.	—

Measure

Time frame

Respiratory symptoms. Timepoint: Before starting treatment (step 0), one (step I) and two months (step II) after starting treatment. Method of measurement: Questionnaire.;Chest wheeze. Timepoint: Before starting treatment (step 0), one (step I) and two months (step II) after starting treatment. Method of measurement: Chest auscultation.;Pulmonary function tests. Timepoint: Before starting treatment (step 0), one (step I) and two months (step II) after starting treatment. Method of measurement: Spirometer.;Cell blood count (CBC). Timepoint: Before starting treatment (step 0), one (step I) and two months (step II) after starting treatment. Method of measurement: Auto analyzer.;Oxidative stress parameters. Timepoint: Before starting treatment (step 0), and two months (step II) after starting treatment. Method of measurement: Standard kits.;Lactate dehydrogenase (LDH) in serum. Timepoint: Before starting treatment (step 0), and two months (step II) after starting treatment. Method of measurement: Standard kits.;Gene expression of IL-18 and IL-1b in sputum. Timepoint: Before starting treatment (step 0), and two months (step II) after starting treatment. Method of measurement: Standard kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShadi Ghaffari

Islamic Azad University

shadighafari6@gmail.com+98 51 3870 4347

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026